Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Nicole Quenelle

Internal Medicine La Jolla, CA Medical Doctor

NPI 1407295983 CMS profile 2789582

10666 N Torrey Pines Rd, La Jolla, CA 92037

Open in the dashboard

General payments

$1,342

60 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Nicole Quenelle of La Jolla, CA is reported in the CMS Open Payments database as having received $1,342 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $149 1
2022 General $99 1
2019 General $1,093 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Quenelle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nicole Quenelle were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nicole Quenelle Internal Medicine median Middle half National median
2019 $1,093 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $99 $141 $42–$496 $149
2023 $149 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. E.R. Squibb & Sons, L.L.C. $284 4 payments
  2. Merck Sharp & Dohme Corporation $139 10 payments
  3. Genentech USA, Inc. $96 3 payments
  4. Amgen Inc. $95 5 payments
  5. Astellas Pharma US Inc $92 5 payments
  6. Janssen Biotech, Inc. $91 3 payments
  7. Novartis Pharmaceuticals Corporation $78 4 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $54 3 payments
  9. Celgene Corporation $53 2 payments
  10. Otsuka America Pharmaceutical, Inc. $38 2 payments
  11. Other $322 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,318 59 payments
  2. Education $24 1 payment
Products named General payments · program years 2019–2023
  1. OPDIVO $165 2 payments
  2. KEYTRUDA $139 10 payments
  3. ERLEADA $91 3 payments
  4. SANDOSTATIN $78 4 payments
  5. VOTRIENT $78 4 payments
  6. Vectibix $71 4 payments
  7. Neulasta $71 4 payments
  8. XOSPATA $60 3 payments
  9. Vitrakvi $54 3 payments
  10. Abraxane $53 2 payments
  11. Other $732 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

2,209

Median for Internal Medicine: 777

Drug cost

$4,744,242

Median for Internal Medicine: $73,373

Branded share of claims

33.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibrance Palbociclib Brand 37 $571,735
Lynparza Olaparib Brand 41 $535,598
Lenalidomide Generic 43 $514,178
Verzenio Abemaciclib Brand 27 $373,280
Pomalyst Pomalidomide Brand 15 $372,473
Brukinsa Zanubrutinib Brand 28 $368,733
Zejula Niraparib Tosylate Brand 12 $346,473
Calquence Acalabrutinib Maleate Brand 24 $345,163
Imbruvica Ibrutinib Brand 18 $262,621
Cabometyx Cabozantinib S-Malate Brand 11 $238,311

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$60,023

Of which drugs: $55,962

Medicare patients

35

Average age 66

Services billed

3,614

18 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 43%
High blood pressure 37%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution , 1000 cc J7030 Office 14 35 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record